Related Experiment Video
Updated: Aug 23, 2026
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Cyclooxygenase-2 and gastrointestinal cancer
Jason R Mann1, Raymond N DuBois
1Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 694 Preston Research Building, Nashville, TN 37232-6838, USA.
Abstract:
The cyclooxygenase (COX) enzymes (COX-1 and COX-2) are key enzymes of prostaglandin (PG) biosynthesis. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of both COX-1 and COX-2. Selective COX-2 inhibitors have been developed that appear to have 50% less gastrointestinal toxicity than traditional nonselective NSAIDs. Experimental evidence suggests that the COX pathway is involved in tumor promotion. Evidence to support this comes from both clinical and laboratory findings suggesting that chronic NSAID use reduces the relative risk for developing colorectal cancer (CRC). Although the precise mechanism or mechanisms by which these drugs affect tumor progression is not completely understood, it is likely that part of their anti-tumor effect is due to inhibition of the COX- 2 enzyme. COX-2 levels are increased in CRC as well as in several other solid malignancies. COX-2-derived bioactive lipid products promote tumor-associated n eovascularization, inhibit cell death, and stimulate cell proliferation and motility. Additionally, treatment with COX-2-selective inhibitors reduces polyp burden in animal models of intestinal neoplasia and in humans with familial adenomatous polyposis (FAP). Ongoing human clinical trails are under way to test the efficacy of COX-2-selective inhibitors in a number of human cancers.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase-2 (COX-2) show promise in reducing colorectal cancer risk. COX-2 inhibition may be a key mechanism in the anti-tumor effects of NSAIDs.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, are crucial for prostaglandin biosynthesis.
- Non-steroidal anti-inflammatory drugs (NSAIDs) traditionally inhibit both COX-1 and COX-2.
- Selective COX-2 inhibitors offer reduced gastrointestinal toxicity compared to nonselective NSAIDs.
Purpose of the Study:
- To explore the role of the COX pathway in tumor promotion.
- To investigate the potential anti-tumor effects of NSAIDs, particularly selective COX-2 inhibitors.
- To understand the mechanisms by which COX-2 inhibition may impact cancer progression.
Main Methods:
- Review of experimental evidence, including clinical and laboratory findings.
- Analysis of the association between chronic NSAID use and colorectal cancer (CRC) risk.
- Examination of COX-2 expression levels in various malignancies.
- Assessment of the impact of COX-2 inhibitors on tumor-associated processes and in preclinical/clinical models.
Main Results:
- Chronic NSAID use is linked to a reduced risk of developing colorectal cancer.
- COX-2 enzyme activity is implicated in tumor promotion, with elevated COX-2 levels observed in CRC and other cancers.
- COX-2-derived products contribute to tumor angiogenesis, apoptosis resistance, and enhanced proliferation/motility.
- COX-2 inhibitors have demonstrated a reduction in polyp burden in animal models and in individuals with familial adenomatous polyposis (FAP).
Conclusions:
- Inhibition of the COX-2 enzyme is likely a significant factor in the anti-tumor effects of NSAIDs.
- COX-2 selective inhibitors represent a potential therapeutic strategy for various cancers.
- Ongoing clinical trials are evaluating the efficacy of COX-2 inhibitors across multiple human cancer types.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:24Peptic Ulcer Disease II: Pathophysiology
02:34Inhibition of Cdk Activity
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...